Cargando…

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection

The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model....

Descripción completa

Detalles Bibliográficos
Autores principales: Sadiq, Muhammad W., Nielsen, Elisabet I., Khachman, Dalia, Conil, Jean-Marie, Georges, Bernard, Houin, Georges, Laffont, Celine M., Karlsson, Mats O., Friberg, Lena E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376394/
https://www.ncbi.nlm.nih.gov/pubmed/27578330
http://dx.doi.org/10.1007/s10928-016-9486-9
_version_ 1782519148468764672
author Sadiq, Muhammad W.
Nielsen, Elisabet I.
Khachman, Dalia
Conil, Jean-Marie
Georges, Bernard
Houin, Georges
Laffont, Celine M.
Karlsson, Mats O.
Friberg, Lena E.
author_facet Sadiq, Muhammad W.
Nielsen, Elisabet I.
Khachman, Dalia
Conil, Jean-Marie
Georges, Bernard
Houin, Georges
Laffont, Celine M.
Karlsson, Mats O.
Friberg, Lena E.
author_sort Sadiq, Muhammad W.
collection PubMed
description The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model. The WB-PBPK model was built using a non-linear mixed effects approach based on data from 102 adult intensive care unit patients. Tissue to plasma distribution coefficients (Kp) were available from the literature and used as informative priors. The developed WB-PBPK model successfully characterized both the typical trends and variability of the available ciprofloxacin plasma concentration data. The WB-PBPK model was thereafter combined with a pharmacokinetic–pharmacodynamic (PKPD) model, developed based on in vitro time-kill data of ciprofloxacin and Escherichia coli to illustrate the potential of this type of approach to predict the time-course of bacterial killing at different sites of infection. The predicted unbound concentration–time profile in extracellular tissue was driving the bacterial killing in the PKPD model and the rate and extent of take-over of mutant bacteria in different tissues were explored. The bacterial killing was predicted to be most efficient in lung and kidney, which correspond well to ciprofloxacin’s indications pneumonia and urinary tract infections. Furthermore, a function based on available information on bacterial killing by the immune system in vivo was incorporated. This work demonstrates the development and application of a WB-PBPK–PD model to compare killing of bacteria with different antibiotic susceptibility, of value for drug development and the optimal use of antibiotics . ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10928-016-9486-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5376394
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-53763942017-04-12 A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection Sadiq, Muhammad W. Nielsen, Elisabet I. Khachman, Dalia Conil, Jean-Marie Georges, Bernard Houin, Georges Laffont, Celine M. Karlsson, Mats O. Friberg, Lena E. J Pharmacokinet Pharmacodyn Original Paper The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model. The WB-PBPK model was built using a non-linear mixed effects approach based on data from 102 adult intensive care unit patients. Tissue to plasma distribution coefficients (Kp) were available from the literature and used as informative priors. The developed WB-PBPK model successfully characterized both the typical trends and variability of the available ciprofloxacin plasma concentration data. The WB-PBPK model was thereafter combined with a pharmacokinetic–pharmacodynamic (PKPD) model, developed based on in vitro time-kill data of ciprofloxacin and Escherichia coli to illustrate the potential of this type of approach to predict the time-course of bacterial killing at different sites of infection. The predicted unbound concentration–time profile in extracellular tissue was driving the bacterial killing in the PKPD model and the rate and extent of take-over of mutant bacteria in different tissues were explored. The bacterial killing was predicted to be most efficient in lung and kidney, which correspond well to ciprofloxacin’s indications pneumonia and urinary tract infections. Furthermore, a function based on available information on bacterial killing by the immune system in vivo was incorporated. This work demonstrates the development and application of a WB-PBPK–PD model to compare killing of bacteria with different antibiotic susceptibility, of value for drug development and the optimal use of antibiotics . ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10928-016-9486-9) contains supplementary material, which is available to authorized users. Springer US 2016-08-30 2017 /pmc/articles/PMC5376394/ /pubmed/27578330 http://dx.doi.org/10.1007/s10928-016-9486-9 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Sadiq, Muhammad W.
Nielsen, Elisabet I.
Khachman, Dalia
Conil, Jean-Marie
Georges, Bernard
Houin, Georges
Laffont, Celine M.
Karlsson, Mats O.
Friberg, Lena E.
A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
title A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
title_full A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
title_fullStr A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
title_full_unstemmed A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
title_short A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
title_sort whole-body physiologically based pharmacokinetic (wb-pbpk) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376394/
https://www.ncbi.nlm.nih.gov/pubmed/27578330
http://dx.doi.org/10.1007/s10928-016-9486-9
work_keys_str_mv AT sadiqmuhammadw awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT nielsenelisabeti awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT khachmandalia awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT coniljeanmarie awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT georgesbernard awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT houingeorges awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT laffontcelinem awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT karlssonmatso awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT friberglenae awholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT sadiqmuhammadw wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT nielsenelisabeti wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT khachmandalia wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT coniljeanmarie wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT georgesbernard wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT houingeorges wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT laffontcelinem wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT karlssonmatso wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection
AT friberglenae wholebodyphysiologicallybasedpharmacokineticwbpbpkmodelofciprofloxacinasteptowardspredictingbacterialkillingatsitesofinfection